| Filed On | Filing |
|---|---|
| 13 Oct 2026 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 04 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September |
| 29 Jul 2026 |
8-K: Regulation FD Disclosure
Investor contact:Jessica [email protected] |
| 28 Jul 2026 |
8-K: Regulation FD Disclosure
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation |
| 15 Jul 2026 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 28 Apr 2026 |
8-K: Submission of Matters to a Vote of Security Holders
(a) The 2026 Annual Meeting of Shareholders of the Company was held on April 23, 2026. |
| 14 Apr 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 21 Jan 2026 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 14 Oct 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 09 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors |
| 16 Jul 2025 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 10 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors |
| 30 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23rd that he will join Goldman Sachs as a Partner. The retirement will be effective May 31, 2025... |
| 15 Apr 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 03 Apr 2025 |
8-K: Regulation FD Disclosure
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims |
| 26 Feb 2025 |
8-K: Other Events
Citigroup Global Markets Limited, Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC (the “Managers”) understand that Johnson & Johnson, a New Jersey corporation (the “Company”), proposes to issue and sell €600,000,000 aggregate... |
| 20 Feb 2025 |
8-K: Other Events
Citigroup Global Markets Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC (the “Managers”) understand that Johnson & Johnson, a New Jersey corporation (the “Company”), proposes to issue and sell $750,000,000 aggregate principal... |
| 22 Jan 2025 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 15 Oct 2024 |
8-K: Results of Operations and Financial Condition
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. |
| 20 Sep 2024 |
8-K: Regulation FD Disclosure
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims |
Loading...